Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy

Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy

<strong>Aims </strong>Hypertrophic cardiomyopathy (HCM) is characterised by left ventricular hypertrophy (LVH), myocardial fibrosis, enhanced oxidative stress and energy depletion. Unbound/loosely bound tissue copper II ions are powerful catalysts of oxidative stress and inhibitors of an...

Full description

Bibliographic Details
Main Authors: Farrant, J, Dodd, S, Vaughan, C, Reid, A, Schmitt, M, Garratt, C, Akhtar, M, Mahmod, M, Neubauer, S, Cooper, RM, Prasad, SK, Singh, A, Valkovic, L, Raman, B, Ashkir, Z, Clayton, D, Baroja, O, Duran, B, Spowart, C, Bedson, E, Naish, JH, Harrington, C, Miller, CA
Other Authors: TEMPEST investigators
Format: Journal article
Language:English
Published: BMJ Publishing Group 2023

Similar Items